title: Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection.
abstract: In a prospective, open-label, 104-week study, patients who were infected with human immunodeficiency virus type 1 (virus load, <50 copies/mL) and who were receiving protease inhibitor-based therapy were randomly assigned to continue treatment with a protease inhibitor or to replace it with abacavir or efavirenz. Treatment failure, defined as virological failure (virus load, >500 copies/microL) or any clinical or biochemical adverse event with a grade of >or=3 (on the basis of the World Health Organization [WHO] or American Heart Association [AHA] scales), was the primary outcome measurement. Failure rates were more frequent in the group treated with protease inhibitors (P<.01), and there were no significant differences in the rate of treatment failure between the group treated with efavirenz and the group treated with abacavir. Tolerability was better in the groups treated with abacavir or with efavirenz versus those treated with protease inhibitors. Fewer patients who received efavirenz experienced viral rebound. Among all groups, the mean increase in the CD4 cell count was 131 cells/microL (P<.001), with no significant difference between groups. This switching strategy maintains optimal levels of virological suppression and may improve lipid profiles in most patients.
authors.affiliation: Division of Infectious Diseases, Ospedali Riuniti, 24128 Bergamo, Italy. franco31556@hotmail.com
authors.forename: Franco
authors.initials: F
authors.lastname: Maggiolo
authors.forename: Diego
authors.initials: D
authors.lastname: Ripamonti
authors.forename: Laura
authors.initials: L
authors.lastname: Ravasio
authors.forename: Giampietro
authors.initials: G
authors.lastname: Gregis
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Quinzan
authors.forename: Annapaola
authors.initials: A
authors.lastname: Callegaro
authors.forename: Claudio
authors.initials: C
authors.lastname: Arici
authors.forename: Fredy
authors.initials: F
authors.lastname: Suter
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors